Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

PHASE1UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
T Cell Lymphoblastic Lymphoma
Interventions
BIOLOGICAL

BT-007 CD7 CAR-T cells

T cells purified from the peripheral blood mononuclear cell (PBMC) of subjects or subjects' relatives which depend on their conditions, transduced with 4-1BB/CD3ζ lentiviral vector, expanded in vitro for future administration.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Bioceltech Therapeutics, Ltd.

INDUSTRY